FDA Explores OpenAI's AI for Faster Drug Evaluations

FDA and OpenAI Discuss AI for Drug Evaluations

The U.S. Food and Drug Administration (FDA) is reportedly discussing the use of artificial intelligence (AI) with OpenAI to expedite drug evaluations. According to Wired, the project, potentially named cderGPT, could significantly streamline the Center for Drug Evaluation (CDE) processes.

The CDE regulates over-the-counter and prescription drugs in the U.S. Drug development often takes over a decade. This collaboration aims to accelerate the later stages of this process. Associates from Elon Musk's DOGE are also reportedly involved in these discussions.

AI's Potential in Drug Development

AI has long been recognized for its potential to revolutionize drug development. While it could make notoriously slow steps more efficient, concerns remain about the reliability and control of AI models. This collaboration between OpenAI and the FDA marks a significant step toward exploring the practical applications of AI in this critical field.

While AI could accelerate a portion of the drug evaluation timeline, questions about the technology's reliability need addressing. This partnership signals a move towards leveraging AI's potential in the pharmaceutical industry.

Source: Wired